← All companies

Merck & Co.

6 reports

Research on this company

J.P. Morgan

J.P. Morgan: Eylea HD use expands: Can Merck’s ophthalmology pipeline catch up?

JPMorgan believes expanded indications and dosing regimens will support continued growth for Eylea HD, although declines in the original Eylea will offset some of that growth. Whether competition from new drugs can change the landscape also depends on payer restrictions and clinical advantages.

Barclays

Barclays: Merck’s personalized cancer vaccine phase III data: Clear recurrence benefit, but commercial potential still depends on durability

INT combined with Keytruda increased the two-year recurrence-free survival rate in melanoma patients by 12.2 percentage points, but the distant metastasis benefit was weaker than in phase II, and overall survival data remain immature. Barclays sees substantial room in postoperative adjuvant treatment and maintains its Overweight rating on Merck.